T he primary function of B lymphocytes is to establish and maintain Ab memory for foreign Ags. It is critical for B cells to distinguish self-Ag from non-self-Ags, which is accomplished through surface-expressed BCRs (1, 2) . Once bound by Ag, the BCR initiates the activation of B cells (1) (2) (3) . Aberrant B cell activation induced by self-Ags is associated with B cell tumors and autoimmune diseases such as systemic lupus erythematosus (SLE), although the underlining mechanisms are incompletely understood (4) (5) (6) . To balance immunoprotection and immunopathology, B cell activation is under strict control by either the activating CD19 or the inhibitory FcgRIIB coreceptor (7) (8) (9) . Early biochemical studies identified that the actions of CD19 and FcgRIIB on the BCR is dependent on the cytoplasmic domains of the respective coreceptor (8, 9) . Mouse model studies demonstrated that Ab responses in CD19-deficient mice are severely impaired (10) (11) (12) , whereas FcgRIIB-deficient mice show susceptibility to autoimmune diseases in some certain genetic backgrounds, consistent with their respective activating and inhibitory functions (13, 14) . Mechanistically, biochemical studies showed that FcgRIIB exerts inhibition of BCR signaling through its ITIM in the cytoplasmic domain to recruit the SH2-domain containing inositol-5-phosphatase SHIP (15) .
The recent application of advanced live-cell imaging technologies to B cell activation studies have provided an updated view of the dynamic, complicated, yet ordered molecular events that follow within seconds of Ag recognition by the BCR. These studies have revealed that BCR microclusters function as a central platform for the signaling cascades that mediate B cell activation (3, 16) , which, in turn, are subject to the regulation imposed by CD19 and FcgRIIB. Batista and colleagues (17) were the first to report the key importance of BCR and CD19 microcluster colocalization in the initiation of BCR signaling, which has been advanced by their recent study using super-resolution microscopy to show the modestly concomitant concentration of BCR and CD19 molecules in Syk signaling microclusters upon BCR-Ag recognition (18) .
Recently, we showed by live cell imaging technique that BCR microclusters change their integrated fluorescence intensity (FI) over time shortly after BCR binding to Ags in a process we termed BCR microcluster growth (19) , which is itself subject to regulation by FcgRIIB (20) . At physiological conditions, B cell activation could be under competitive regulation by both FcgRIIB and CD19 coreceptors. In this study, we used total internal reflection fluorescence microscopy (TIRFM)-based, high-resolution, high-speed live-cell and molecule imaging techniques to show that FcgRIIB can efficiently disrupt the spatial-temporal colocalization of BCR and CD19 microclusters within B cell immunological synapse (IS), suggesting a new inhibitory function of FcgRIIB. Moreover, we showed that this inhibitory feature relies on the transmembrane (TM) domain of FcgRIIB and not the ITIM-containing cytoplasmic domain, suggesting that TM domain based protein-protein and protein-lipid interactions may play an important role in the regulation of receptor-mediated cross-membrane signaling transduction. We linked these findings to clinical diseases demonstrating that primary B cells from SLE patients harboring the single nucleotide polymorphism I232T within the TM of FcgRIIB, a mutation previously shown to be significantly associated with SLE in its homozygous format (21, 22) , have lost the ability to block the synaptic colocalization of BCR with CD19 and downstream signaling molecular microclusters. This inhibitory function of FcgRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell IS may help explain the reported hyper-reactive features of SLE patient B cells (4) (5) (6) .
Materials and Methods

Mice, cells, Ags, and Abs
B1-8-specific B cells were isolated from spleens of IgH B1-8/B1-8 Igк
2/2 transgenic mice as described previously (19) . A20II1.6, Ramos, and ST486 B cell lines were gifts for laboratory scientific studies from Dr. Susan K. Pierce (National Institute of Allergy and Infectious Diseases, National Institutes of Health [NIH] ), all of which were originally purchased from American Type Culture Collection. Biotin-conjugated goat F(ab9) 2 antimouse IgG, biotin-conjugated goat F(ab9) 2 anti-human IgA+IgG+IgM (H+L), and rabbit Fab anti-mouse IgG specific for Fc5m were purchased from Jackson Immunoresearch Laboratory. Pacific Blue-conjugated mouse mAb anti-human CD19 and FITC-conjugated mouse mAb anti-human CD19 (clone HIB19) were obtained from eBioscience. Biotin-conjugated anti-mouse CD32/CD16 (clone 2.4G2) was purchased from BD. Biotinconjugated anti-human CD32 (clone AT10) was purchased from AbD Serotec. Alexa 647-conjugated goat Fab anti-human IgM specific for Fc5m and secondary Ab Alexa Fluor 568-conjugated F(ab9) 2 )-specific Abs were purchased from Cell Signaling Technology. Goat Fab antimouse CD19 (clone 1D3) and mouse Fab anti-human CD19 (clone HIB19) were made by using Fab micropreparation kit following a protocol in our published studies (19, 20, (23) (24) (25) . Conjugations of Abs with Alexa Fluor (Alexa Fluor 405, 488, 568, or 568) were carried out using Alexa Fluor mAb labeling kits (Molecular Probes) following manufacturer's protocols, whereas biotinylating Abs were carried out following manufacturer's protocols of EZLink Sulfo-NHS-LC-Biotin (Thermo Scientific).
Plasmid constructs and transfections
The pEYFP-N1 was purchased from Clontech, and the YFP gene in this plasmid was modified using a QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) to reduce the dimerization of GFP as suggested in the published study (26) . pBLUEScript plasmids containing mouse FcgRIIB1 and pMSCVpuro plasmids containing human FcgRIIB wild type (WT) or I232T loss-of-function mutant were kindly provided by Z.I. Honda (Tokyo University, Tokyo, Japan) (21) . Using these plasmids as templates, the genes encoding mouse or human FcgRIIB were amplified by PCR and inserted into pEYFP-N1, via the restriction enzyme sites SacII and HindIII. In the case of mouse FcgRIIB, the Bgl II restriction site AGATCT carried by mouse FcgRIIB itself was synonymously mutated to AGACCT using a QuikChange Mutagenesis Kit (Stratagene), and mutants were generated by PCR. The sequences of the cloned fragments were confirmed by dideoxy sequencing, and the cDNAs of DL238, Y235F, DL238-Y235F, FFTM, FF-TM-DL238, and LAT-TM-DL250 were cloned into pEYFP-N1. For the expression vector constructs, A20II1.6 cells and ST486 cells were transfected by electroporation, selected for growth in 0.5 or 1 mg/ml G418, and sorted to equivalent levels of FcgRIIB expression using flow cytometry in conjunction with anti-FcgRIIB-specific Abs. Similarly, plasmids containing the cDNA of human FcgRIIB WT or I232T were transfected into either A20II1.6 mouse B cells or ST486 human B cells, and stable subline B cells expressing equivalent level of human FcgRIIB-WT or FcgRIIB-I232T were sorted at least two rounds by flow cytometry.
SLE patients and healthy control subjects and FcgRIIB TM domain genotyping Thirty-seven patients fulfilling the revised SLE classification criteria of American College of Rheumatology were enrolled in this study. Twentynine females and 8 males with ages ranging from 12 to 62 y with mean age of 34 6 15 y were included. Healthy volunteers were recruited as control subjects. The ethics committee of Peking Union Medical College Hospital approved this study, and informed consents were obtained from each patient and healthy volunteer. Four to 8 ml peripheral blood was acquired from SLE patients and healthy volunteers. The PBMCs were isolated from these samples by subjecting to Ficoll-Paque PLUS density separation and frozen until imaging experiments. Genomic DNA was extracted from peripheral blood samples using the TIANamp Blood DNA Midi Kit (TIANGEN BIOTECH, Beijing, China) following the manufacturer's protocol. To identify the TM region of FcgRIIB1 nucleotide polymorphism, we performed PCR by using primers (forward: 59-AAGGGGAGCCCTTCC-CTCTGTT-39, reverse: 59-CATCACCCACCATGTCTCAC-39) binding to the flanking introns of exon 5 as reported previously (21, 22) . The DNA sequencing was done by BGI (Beijing, China).
Intracellular immunofluorescence staining and molecular imaging
Recruitment of signaling molecules into the IS of B cells upon encountering surrogate Ags tethered on planar lipid bilayer (PLB) membranes was imaged by TIRFM following our published protocol with modifications (19, 20, 24, 25 2 goat Abs specific for rabbit IgG (Invitrogen) staining as previously described (19, 20, 24, 25) . Images were analyzed by ImageJ (NIH) software following our published protocols (19, 20, 24, 25) .
Preparation of PLBs
PLBs were prepared containing biotin lipids to which biotinylated BCR and FcgRIIB ligands were attached through streptavidin following our published protocol (19, 20, 25, 27) and were provided as online repository materials. In brief, biotin liposomes were prepared by sonication of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-cap-biotin (Avanti Polar Lipids) in a 25:1 molar ratio in PBS at a lipid concentration of 2.5 mM. The PLBs were formed in Lab-Tek chambers (Nalge Nunc) in which the cover glasses were replaced with nanostrip-washed coverslips. The coverslips were incubated with 0.1 mM biotin liposomes in PBS for 15 min. After washing with 10 ml PBS, the PLB was incubated with 50 nM streptavidin for 15 min, and excessive streptavidin was removed by washing with 10 ml PBS. The streptavidin-containing PLBs were incubated for 15 min with either 20 nM biotinylated goat F(ab9) 2 were ready to be used in total internal reflection fluorescence (TIRF) imaging.
Molecular imaging by confocal fluorescence microscopy A20II1.6 cells were stained with Alexa Fluor 568-conjugated goat Fab antimouse CD19 (clone 1D3) and Alexa Fluor 405-conjugated rabbit Fab antimouse IgG specific for Fc5m and washed twice, then placed on PLB membranes containing surrogate Ags to cross-link BCR alone or to coligate BCR and FcgRIIB for 15 min at 37˚C, 5% CO 2 , and then fixed with 4% paraformaldehyde. Images of stained molecules were captured by confocal fluorescence microscope (LSM710-3channel; Zeiss) with a 1003 oil objective lens. Images were analyzed using ImageJ (NIH) software as reported in our previous studies (19, 20, 25, 27) . In brief, images were subtracted for background and then marked with regions of interest (ROIs).
The mFI values obtained were the ratio of integrated FI of the ROIs to the total area of pixels in the same ROIs.
Mathematical quantification of BCR, pSyk, pCD19, and p-PI3K microclusters for FI information using a Matlab-based two-dimensional Gaussian analysis algorithm
The mathematical quantification of BCR, pSyk, pCD19, and p-PI3K microclusters for precise FI information was performed following our published protocol by a Matlab-based two-dimensional Gaussian analysis algorithm. Through this analysis, precise two-dimensional positions and integrated FIs of these microclusters can be acquired by means of least squares fitting of a two-dimensional Gaussian function. Such a twodimensional Gaussian function is used to quantify each of the twodimensional FI profiles. Because the profiles of some of these microclusters in TIRFM images were not perfectly circularly shaped, we thus allowed the Gaussian function to analyze an elliptical shape. The two-dimensional Gaussian function used in this study is provided (19) :
We define the ellipticity by
We define the two-dimensional width of each microcluster as
Through the two-dimensional Gaussian mathematical fitting, we are able to get several key parameters for each microcluster including the position (x c , y c ), integrated FI (I), background FI (z 0 ), and full width at half-maximum peak height of the intensity distribution.
Images processing, mathematical, and statistical analyses
Unless specifically indicated, the display range of a set of TIRFM images in each figure is the same to allow direct visional comparison of intensity. The colocalization index of BCR and CD19 or BCR and signaling molecules microclusters within the IS were calculated based on the intensity correlation analysis as described previously (19, 20, 24, 25) . In this report, the mathematical quantifications by means of Pearson's correlation index (PCI) analyses for the synaptic distribution of two molecules of interest were analyzed by the WCIF plugin of ImageJ software. Student t tests were performed for statistical comparisons. A p value ,0.05 was considered to indicate a significant difference.
Results
FcgRIIB efficiently blocks synaptic colocalization of BCR and CD19 microclusters through its TM domain
First, we asked whether the colocalization of BCR and CD19 microclusters could be regulated by the BCR inhibitory coreceptor FcgRIIB. To do so, we imaged the spatial and temporal distribution of both BCR and CD19 microclusters within the IS by TIRFM on human Ramos B cells that were placed on PLBs. Using an improved experimental system that is similar to the ones in our published report (20), we simultaneously tethered goat anti-human IgM F(ab9) 2 fragment and mouse anti-FcgRIIB mAb to PLBs to co-ligate BCR and FcgRIIB. To cross-link BCR alone, we used goat anti-human IgM F(ab9) 2 fragment and the isotype matched mouse mAb. The colocalization of BCR and CD19 microclusters was quantified by the PCI following our published protocol (24, 25, 27) . Co-ligation of the BCR with FcgRIIB did not affect the colocalization of the BCR and CD19 after 5 min of engagement with the PLBs (p = 0.4056; Fig. 1A and 1B). However, BCR and CD19 colocalization was significantly disrupted at 10 min (p = 0.0012; Fig. 1C and 1D ) and continued to be so at 15 min (p , 0.0001; Fig. 1E and 1F ). The accumulation of BCR and CD19 into the IS was also downregulated by FcgRIIB and is consistent with our and others' previous reports (20, 28, 29) . We also assessed the colocalization of BCR and CD19 microclusters using primary B cells from IgH B1-8/B1-8 Igk cross-link B1-8 BCR alone). These results confirmed that BCR and CD19 colocalization was obviously inhibited by FcgRIIB in mouse primary B cells (Supplemental Fig. 1A) .
Next, we addressed the molecular mechanism of the inhibitory function of FcgRIIB by transfecting a series of FcgRIIB mutants into A20II1.6 mouse B cells lacking endogenous FcgRIIB (Fig. 2A) . These mutants showed proper plasma membrane localization and equivalent level of cell-surface expression (Supplemental Fig. 1B) , consistent with earlier studies (32) . FcgRIIB-WT potently disrupted the synaptic colocalization of BCR and CD19 microclusters (Fig. 2B) . Unexpectedly, we found that FcgRIIB-DL238, which lacks the entire cytoplasmic domain ( Fig. 2A) , also showed equally efficient inhibitory ability as the FcgRIIB-WT (Fig. 2C) . Earlier biochemical studies reported that tyrosine 235 (Y235), which is predicted to be located proximal to the inner leaflet of plasma membrane, is phosphorylated upon co-ligation of BCR and FcgRIIB (32) . Because Y235 is intact in FcgRIIB-DL238, we tested the function of this residue by examining BCR and CD19 colocalization in B cells expressing a Y235 to F235 point mutation in either WT FcgRIIB (FcgRIIB-Y235F) or the truncation mutant FcgRIIB-DL238 (FcgRIIB-DL238-Y235F; Fig. 2A ). We found that FcgRIIB-Y235F still maintained its inhibitory function (p = 0.0021; Fig. 2D ) and FcgRIIB-DL238-Y235F only mildly impaired the synaptic colocalization of BCR and CD19 (p = 0.0778; Fig. 2E ). These results suggest that the TM domain, but not the cytoplasmic domain, of FcgRIIB might be responsible for its inhibitory function. To confirm this speculation, we swapped the type I TM domain of FcgRIIB-WT with a type I TM domain of similar length from the fruit fly neural-cadherin protein (FcgRIIB-FF-TM; Fig. 2A ). In the transfected A20II1.6 B cells, FcgRIIB-FF-TM showed good plasma membrane location and comparable surface expression as FcgRIIB-WT ( Supplemental  Fig. 1B) . PCI analyses on BCR and CD19 TIRFM images indicated that FcgRIIB-FF-TM completely lost the ability to block the synaptic colocalization of BCR and CD19 (p = 0.1585; Fig. 2F ), endorsing this new inhibitory function of FcgRIIB depends on its TM domain, but not the cytoplasmic tail.
FcgRIIB can inhibit BCR and CD19 colocalization under the same synaptic recruitment efficiency of BCR (or CD19) microclusters PCI is a reliable tool to quantify the codistribution of two molecules and has been widely used by us and others to quantify TIRFM images (17, 19, 24, 25, 27) . However, it is in principle an intensitybased method that can produce reduced PCI values resulting from a reduction in the mean FI (mFI) of one of the molecules in the ROI being analyzed. Therefore, we compared the inhibitory function of FcgRIIB-WT and FcgRIIB-FF-TM under co-ligating conditions for the BCR and FcgRIIB when equivalent amounts of BCR or CD19 molecules were recruited to the IS (Supplemental Fig. 1C) . Still, FcgRIIB-FF-TM lost the ability to block the synaptic colocalization of BCR and CD19 microclusters compared with FcgRIIB-WT (Supplemental Fig. 1D ). To circumvent the inhibitory effects from the cytoplasmic tail of FcgRIIB, we made an additional mutant FcgRIIB-FF-TM-DL238, in which the TM domain of the truncation mutant FcgRIIB-DL238 (see Fig. 2A ) was swapped with the TM domain of fruit fly neural-cadherin protein (Supplemental Fig. 2A ). FcgRIIB-DL238 or FcgRIIB-FF-TM-DL238 was expressed at the surface of A20II1.6 mouse B cells to comparable levels (Supplemental Fig. 2B ) and equivalent levels of BCR, or CD19 was recruited to the IS of both cell types (Supplemental Fig.  2D ). As expected, FcgRIIB-DL238 maintained and FcgRIIB-FF-TM-DL238 lost its ability to block the synaptic colocalization of BCR and CD19 microclusters (Supplemental Fig. 2E ). These analyses confirmed that the TM domain of FcgRIIB has the ability to inhibit the synaptic colocalization of BCR and CD19 microclusters. However, we cannot exclude the possibility that the decreased colocalization of BCR and CD19 microclusters is also contributed by the impaired recruitment of BCR and CD19.
A loss-of-function FcgRIIB I232T mutant in SLE patients is incapable of blocking the synaptic colocalization of BCR and CD19 microclusters
Early epidemiological studies demonstrated a loss-of-function polymorphism in the TM domain of human FcgRIIB (FcgRIIB-I232T) in SLE patients where FcgRIIB-I232T cannot perturb and associate with sphingolipid-and cholesterol-rich lipid raft microdomains upon BCR and FcgRIIB co-ligation (20) (21) (22) . Because this mutation lies within the TM domain, we next tested its function to regulate the synaptic colocalization of BCR and CD19 microclusters by expressing FcgRIIB-I232T in A20II1.6 B cells. As expected, FcgRIIB-WT potently inhibited the colocalization of BCR and CD19, whereas the FcgRIIB-I232T mutant did not (Fig. 3A-C) . Similar results were obtained in human ST486 B cells lacking endogenous FcgRIIB (Fig. 3D-F) . We confirmed that FcgRIIB-WT and FcgRIIB-I232T show good plasma membrane location and comparable surface expression on the cells that were imaged by TIRFM ( Supplemental Fig. 3A ).
The inability of FcgRIIB-I232T to block the synaptic colocalization of BCR and CD19 could be a result of the impaired recruitment of FcgRIIB-I232T to the B cell IS compared with FcgRIIB-WT. To check this point, we simultaneously examined the recruitment of BCR, FcgRIIB, and CD19 into the IS of human ST486 B cells using an advanced three-color-TIRFM time-lapse imaging approach (Fig. 4A, 4B, Supplemental Fig. 3B, 3C , and Supplemental Videos 1-7). The kinetics of FcgRIIB-WT or FcgRIIB-I232T accumulation into the IS was analyzed following our published protocol (20, 24, 25, 33) . We found that both molecules were equally recruited to the B cell IS under co-ligating conditions compared with BCR cross-linking alone (Fig. 4A, 4B,  Supplemental Fig. 3B, 3C , and Supplemental Video 5). We also performed the PCI analysis to quantify the colocalization of BCR with either FcgRIIB-WT or FcgRIIB-I232T. We found that BCRs similarly colocalized with either FcgRIIB-WT or FcgRIIB-I232T after co-ligation (Supplemental Fig. 3D and Supplemental Videos 2 and 4), suggesting a similar physical cross-linking effect in the process of BCR and FcgRIIB co-ligation. These two independent analyses demonstrated that the defect of FcgRIIB-I232T is not due to the impaired recruitment of FcgRIIB-I232T to the B cell IS compared with the case of FcgRIIB-WT upon its co-ligation to BCRs.
Lastly, we quantified the colocalization dynamics of the BCR and CD19 using PCI analysis over the time lapse and found an obvious increase in colocalization efficiency of BCR and CD19 microclusters shortly after the initiation of B cell activation regardless of FcgRIIB involvement (Fig. 4C, 4D , and Supplemental Videos 6 and 7). However, starting at 3-5 min, FcgRIIB-WT but not the FcgRIIB-I232T mutant impaired the synaptic colocalization of BCR and CD19 microclusters (Fig. 4C and 4D) . These results are consistent with the end-point evaluations of human Ramos B cells (Fig. 1) and primary human B cells (Fig. 5 and Supplemental Fig. 4 ) discussed in further detail later in this report, demonstrating again that FcgRIIB relies on its TM domain to efficiently block the synaptic colocalization of BCR and CD19 microclusters.
Reduction in the colocalization of BCR and CD19 is mainly specific to the lipid raft regions
The experiments using the human loss-of-function mutant FcgRIIB-I232T suggested that the association of FcgRIIB with lipid rafts plays an important role in regulating the colocalization of BCR and CD19 microclusters. We were curious to know where BCR and CD19 show the colocalization, in the lipid-raft-rich or in the lipidraft-poor regions. We used lipid raft marker Lyn-m16-CFP to probe the lipid rafts on the plasma membrane and checked the distribution of BCR (or CD19) microclusters in the condition of BCR cross-linking alone or BCR and FcgRIIB co-ligation. We observed much higher efficiency of BCR and CD19 colocalization in lipid-raft-rich regions (strong Lyn-m16-CFP FI microdomain) compared with lipid-raft-poor regions (weak Lyn-m16-CFP FI microdomain; Supplemental Fig. 3E ), suggesting BCR and CD19 mainly colocalized in the lipid raft regions (Supplemental Fig. 3F  and 3G ). More importantly, a comparison of the synaptic colocalization of BCR and CD19 in the condition of BCR cross-linking alone or BCR and FcgRIIB co-ligation suggested that the observed reduction in the colocalization of BCR and CD19 is mainly specific to the lipid-raft-rich regions (Supplemental Fig. 3H and 3I ). Then we asked whether the defect of FcgRIIB-I232T can be reversed by substituting its TM domain with the TM domain of a lipid-raftresident protein, like LAT. To test this hypothesis, we made the construct of FcgRIIB-LAT-TM-DL250, in which the TM domain of human FcgRIIB is substituted with the TM domain of LAT and the cytoplasmic domain of FcgRIIB is truncated ( Supplemental  Fig. 2F) . We checked the effects of FcgRIIB-LAT-TM-DL250 in inhibiting the synaptic colocalization of BCR and CD19 in TIRFM imaging experiments. It is clear that FcgRIIB-LAT-TM-DL250 did not show such an inhibitory function (Supplemental Fig. 2G) , suggesting a constitutive lipid-raft-residing TM cannot inhibit the colocalization of BCR and CD19 microclusters.
Impaired synaptic colocalization of BCR and CD19 microclusters downregulate the recruitment of signaling molecules to membrane proximal signalosome Recent high-resolution and high-speed live-cell imaging experiments have revealed the nature of the dynamic recruitment of intracellular signaling molecules to the IS and BCR microclusters, which, in turn, transduce BCR signals and ultimately activate B cells (3, 16) . In this study, we examined how FcgRIIB will regulate the synaptic recruitment of two such early signaling molecules, Syk and PI3K, into the BCR signalosome by TIRFM. Under co-ligating conditions, we found that FcgRIIB-WT efficiently impaired the synaptic colocalization of BCR and pSyk microclusters (Fig. 6A-C) and the recruitment of pSyk molecules into the IS (Fig. 6E) . However, the FcgRIIB-I232T mutant failed to show such inhibitory function (Fig. 6A, 6B, 6D , and 6F). Because phosphorylation at Y482 and/or Y513 of CD19 is needed to recruit PI3K to the membrane proximal BCR signalosome (9, 18, 34), we next examined the effect of FcgRIIB on the synaptic colocalization of phosphorylated CD19 to BCRs within the IS. FcgRIIB-WT potently blocks the synaptic accumulation of pCD19 in the IS and colocalization of pCD19 and BCR microclusters, whereas FcgRIIB-I232T loses these capabilities (Fig. 7) . Finally, using an anti-p-PI3K p85 (Tyr 458 )/p55 (Tyr 199 ) Ab (35), we showed that the synaptic recruitment of the phosphorylated PI3K p85 subunit (termed p-PI3K in this report) and its colocalization with BCR is inhibited by FcgRIIB-WT, but not FcgRIIB-I232T (Fig. 8) . Together, these results demonstrate that the impaired synaptic colocalization of BCR and CD19 microclusters contributes to the inhibition in the recruitment of signaling molecules to the membrane proximal signalosome.
FcgRIIB-I232T does not inhibit the integrated FI change of pCD19, pSyk, and p-PI3K microclusters when co-ligated to the BCR Recent studies show that BCR microcluster functions as a central platform for the signaling cascades of B cell activation (3, 16, 36) . To understand how FcgRIIB might modulate downstream BCR effector molecules, we imaged thousands of BCR and BCR signaling molecule microclusters, including pSyk, pCD19, and p-PI3K, within the IS by TIRFM, and computed the changes of these microclusters in terms of integrated FI through a Matlab algorithm-driven two-dimensional Gaussian fitting protocol as reported in our published studies (19, 20, 25, 27) . Accordingly, FcgRIIB-WT dampened the FI of BCR microclusters by 84.3% in B cells under co-ligation conditions compared with B cells activated by BCR cross-linking alone (Fig. 9A and 9B ), consistent with our published studies quantifying the function of WT mouse FcgRIIB on BCR microclusters (20) . In contrast, the FcgRIIB-I232T showed only a partial inhibitory effect with a 60.3% reduction in FI (Fig. 9A and 9B) . Clearly, the growth features of BCR microclusters is subjected to downregulation by not only the TM, but also the cytoplasmic domains of FcgRIIB, consistent with the fluorescence resonance energy transfer data in our early report (20) . When we quantified pCD19 (Fig. 9C and 9D) , pSyk ( Fig. 10A  and 10B) , and p-PI3K (Fig. 10C and 10D ) microclusters, we found that FcgRIIB-I232T mutant completely lost the ability to inhibit the growth in integrated FI of these microclusters compared with FcgRIIB-WT. These results suggest that the conversion of BCR microclusters from signaling inactive to active state is under strict regulation by the TM domain of FcgRIIB.
Primary B cells from SLE patients bearing the FcgRIIB-I232T homozygous mutant show defects in blocking early B cell activation events
We next studied the inhibitory function of FcgRIIB in primary B cells from SLE patients and healthy control subjects. B cells from peripheral blood was obtained from 6 healthy control subjects and 37 diagnosed SLE patients, and genotyping of FcgRIIB was performed following reported protocol (22) . Only three SLE patients were homozygous for the FcgRIIB-I232T mutation, consistent with a ,10% incidence of homozygosity in epidemiological studies for Asian populations (5, (37) (38) (39) (40) (41) . For live-cell TIRF imaging experiments, B cells were obtained from three donors with sex and age selected from the following categories: SLE patients heterozygous or homozygous for FcgRIIB-I232T, SLE patients WT for FcgRIIB, healthy donors heterozygous for FcgRIIB-I232T, and healthy donors WT for FcgRIIB. The nine SLE patients registered for the TIRF-based in vitro cell biology study presented with a similar severity of clinical lupus syndrome.
In our imaging analyses, we found that B cells from healthy individuals WT for FcgRIIB (Fig. 5A) or heterozygous for FcgRIIB-I232T (Fig. 5B) blocked the synaptic colocalization of IgM-BCR and CD19 microclusters. Intriguingly, B cells from SLE patients WT for FcgRIIB (Fig. 5C ) or heterozygous for FcgRIIB-I232T (Fig. 5D ) also responded similarly to Ag activation. However, strikingly, for B cells from SLE patients homozygous for FcgRIIB-I232T, a severe defect in blocking the synaptic colocalization of IgM-BCR and CD19 microclusters was observed (Fig. 5E ). Because primary B cells can be positive for either IgM-BCR or IgG-BCR in human peripheral blood (35), we also analyzed in parallel the synaptic colocalization of IgG-BCRs with CD19 microcluster and found similar results (Supplemental Fig. 4A-C) .
Furthermore, we found that B cells from SLE patients WT for FcgRIIB (Fig. 11A, 11D, and 11G) or heterozygous for FcgRIIB-I232T (Fig. 11B, 11E , and 11H) efficiently disrupted the synaptic colocalization of BCR and p-PI3K within microclusters. However, B cells from SLE patients homozygous for FcgRIIB-I232T completely lost the ability to block BCR and p-PI3K colocalization, and thus the ability to impair the recruitment of p-PI3K to the IS (Fig. 11C, 11F , and 11I), suggesting hyper-activated PI3K signaling. We conclude that B cells of SLE patients homozygous for the TM domain FcgRIIB-I232T mutant show defects in blocking early activation events, re-emphasizing the importance of this domain in maintaining the balance of immunoprotection and immunopathology.
Discussion
B cell activation is under strict control by BCR activating and inhibitory receptors that are usually coexpressed on the cell surface. In this report, we identified a previously uncharacterized inhibitory function of FcgRIIB that is dependent on its TM domain to block the synaptic colocalization of BCR and CD19 microclusters. Unexpectedly, this inhibitory function does not require the wellcharacterized inhibitory ITIM motif present in the cytoplasmic domain (8, 15, (42) (43) (44) . We propose that the TM domain provides an extra layer of inhibitory function for FcgRIIB to secure its unique position as the only inhibitory IgG FcR to downregulate immune responses (45) . Indeed, the data in this report support the concept that FcgRIIB is a potent inhibitory coreceptor against B cell activation by two mutually integrated mechanisms: 1) impairing the synaptic recruitment of BCR and CD19 molecules, and 2) destabilizing the synaptic colocalization of BCR and CD19 microclusters. Cambier and colleagues (32, 46) were the first to report the importance of the TM domain of FcgRIIB in inhibiting B cell activation, demonstrating that FcgRIIB-mediated dephosphorylation of CD19 relies on the TM domain but not the cytoplasmic tail of FcgRIIB. Although the molecular mechanism remains unclear, we speculate that our results, showing that the TM domain of FcgRIIB can inhibit the recruitment of CD19 to the B cell IS, may help explain their observations. The importance of the FcgRIIB TM domain is also supported by a rich amount of epidemiological studies that have revealed a strong positive association of the FcgRIIB-I232T mutant with SLE disease (7). The I232T polymorphism and its conferred susceptibility to human SLE when homozygous were first identified in Japanese, Chinese, and Thai populations (5, (37) (38) (39) (40) (41) , and then later in African (47) and white populations (6, 48) .
How does the TM domain of FcgRIIB exert its inhibitory effect independent of the cytoplasmic ITIM motif? Although we do not understand the exact mechanism, we speculate that the TM domain modulates the association of FcgRIIB with lipid rafts. Such association has been reported by us and others (20) (21) (22) . A number of cell biological studies have clearly shown the importance of the dynamic interaction of lipid rafts and TM domain of a protein in the activation of B cells (49) . Indeed, the respective interaction patterns of lipid rafts with BCR, CD19, or FcgRIIB are quite different. The association of BCR with lipid rafts is transient and dynamic (50, 51), whereas FcgRIIB-WT with lipid rafts is rather in a rapid and sustained manner (20) . More importantly, the interaction of BCR and lipid rafts is under the dual regulation by FcgRIIB and CD19. It was found that BCR cross-linking alone induces the translocation of BCRs into the lipid raft microdomain; however, upon co-ligation with FcgRIIB, FcgRIIB destabilized BCR and lipid rafts interactions (29) . Several other studies have also revealed that CD19, when co-ligated with the BCR, increases the amount of BCRs that are translocated into lipid rafts and prolongs their residency, which likely accounts for the enhanced B cell activation (52, 53) . Based on these data, we speculate that the sustained condensing of raft lipids around the TM domain of FcgRIIB molecules could be very effective in blocking the subsequent association of lipid raft microdomains with either BCR or CD19 microclusters. Our speculation is partially supported by early studies that showed the FcgRIIB-I232T mutant is unable to associate with the lipid raft microdomain upon co-ligation with the BCR (20) (21) (22) .
Then, a following question is: can the TM domain of a lipid-raftresident protein, like LAT, substitute the function of the TM domain of FcgRIIB? We tested this hypothesis and found that a chimeric construct of FcgRIIB-LAT-TM-DL250 carrying the TM of LAT did not show such inhibitory function. These results suggest that a sole constitutive lipid-raft-residing TM cannot inhibit the colocalization of BCR and CD19 microclusters. There could be two explanations for this result: first, the sequence of the TM domain of FcgRIIB is also important in exerting its inhibitory function to impair BCR and CD19 colocalization. Second, there is an early report by Sohn et al. (29) showing that FcgRIIB is not located in lipid raft regions in quiescent B cells but is translocated to the lipid rafts upon BCR and FcgRIIB co-ligation. Thus, it is possible that the co-ligation-induced interaction of the TM domain of FcgRIIB with lipid rafts might play an important role in inhibiting the colocalization of BCR and CD19. Regardless, together, these data suggest that the complex regulatory network by FcgRIIB and CD19 functions to balance the interaction of BCR and lipid rafts. Obviously, such a sophisticated network shall be important to maintain an appropriate response of B cells upon Ag recognition, and by doing so, secures a perfect homeostasis, balancing immunoprotection and immunopathology.
Three important points emerge from our results using advanced three-color time-lapse TIRF imaging to interpret the inhibitory function of FcgRIIB TM domain. First, FcgRIIB-WT or FcgRIIB-I232T mutant shows comparable recruitment into the B cell IS in response to BCR and FcgRIIB co-ligation, signifying that the inability of FcgRIIB-I232T to inhibit is not because of its impaired synaptic recruitment; moreover, PCI analyses showed that BCRs similarly codistribute with either FcgRIIB-WT or FcgRIIB-I232T after BCR and FcgRIIB co-ligation, suggesting a similar physical cross-linking effect in both cases, Second, FcgRIIB-I232T can still partially impair the growth feature of BCR microclusters, but fully loses the ability to inhibit the growth of pCD19, pSyk, and p-PI3K microclusters. These results indicate that synaptic recruitment of BCRs is subjected to the regulation of the TM and the cytoplasmic tail domain of FcgRIIB, whereas the recruitment of signaling molecules is more likely to be controlled by the TM domain of FcgRIIB. Third, PCI analyses on the dynamic pattern of the synaptic codistribution of BCR and CD19 in human ST486 B cells demonstrated an increase of colocalization of these molecules within 5 min of B cell activation. Starting at 5 min under co-ligation conditions, FcgRIIB-WT but not the FcgRIIB-I232T mutant impaired the colocalization. These results indicate that a certain responding time is needed for FcgRIIB to inhibit the synaptic colocalization of BCR and CD19 microclusters through its TM domains. This point is also supported by the results from human Ramos B cells (10 min responding time) and from primary human B cells (10 min responding time). We do not have a clear mechanism to precisely explain why FcgRIIB needs such a responding time to inhibit the synaptic colocalization of BCR and CD19 microclusters. We assume that FcgRIIB can only execute its ability to inhibit the colocalization of BCR and CD19 microclusters upon the accumulation of sufficient amount of FcgRIIB molecules after BCR and FcgRIIB co-ligation. Our hypothesis is partially supported by the first two points as discussed earlier. Our hypothesis is also supported by two extra independent analyses: first, the synaptic accumulation of FcgRIIB plateaued in 5-8 min after BCR and FcgRIIB co-ligation; second, Pearson's correlation coefficient for BCR and FcgRIIB plateaued around 5 min after co-ligation, suggesting the existence of a responding time to accumulate sufficient amount of FcgRIIB molecules near BCR microclusters. Because FcgRIIB-WT and FcgRIIB-I232T show no differences in these two analyses, we propose that such an inhibitory effect also requires the ability of FcgRIIB to associate with lipid rafts. Thus, our model is that only when a sufficient amount of FcgRIIB-WT, but not the loss-offunction mutant FcgRIIB-I232T, is accumulated to the IS could FcgRIIB-WT block the colocalization of BCR and CD19 microclusters by destabilizing the association of CD19 and/or BCR with lipid rafts. It is our current endeavor to examine these hypotheses by using mathematical calculation-based molecule simulation and super-resolution imaging approaches.
In this report, we also showed that colocalized BCR and CD19 microclusters are more frequently observed at the periphery of the B cell IS, consistent with the published work of Batista and colleagues (17) . Their study showed that BCR and CD19 microclusters highly colocalize as the B cell spreads, such that when the B cell reaches its maximal spreading phase, .45% of Agassociated BCR microclusters are colocalized with CD19 microclusters. But, as Ag-associated BCR microclusters contract into the central supramolecular activation cluster (cSMAC), that is, the central region of the B cell IS, colocalization of BCR and CD19 microclusters decreases. However, in this report, we observed that the colocalization of BCR and CD19 microclusters increases within 5 min and then quickly plateaus. Over the next 10 min, only a very mild decrease of colocalization efficiency occurs. This discrepancy can be reconciled by the fact that there is a lack of an obvious contraction phase of BCR microclusters into a cSMAC in human B cells in our experimental system. Indeed, a TIRF imaging study by Davey et al. (35) showed that in contrast with mouse B cells, human B cells display only subtle contraction responses after maximal spreading, and thus do not form a wellorganized cSMAC even 10 min after encountering Ags. Similarly, we observed a continuous spreading response after 15 min for Ramos and ST486 human B cell lines and 30 min for human primary B cells. The spreading dynamics of human B cells on Agcontaining PLBs, therefore, may explain why the colocalization of BCR and CD19 microclusters increases and then plateaus over time in our experiments. From this point of view, the observations in this report are not inconsistent with data from Batista and colleagues (17) that BCR and CD19 microclusters highly colocalize during the B cell spreading phase. In conclusion, the inhibitory role of the FcgRIIB TM domain in BCR signaling may functionally explain the severely hyper-reactive features of SLE patient B cells (4) (5) (6) 21) .
